Two-Year Biomarker Trends and Kidney/Mortality Outcomes After Semaglutide Versus Phentermine–Topiramate and Naltrexone–Bupropion in People With Obesity and Without Diabetes

Key Points

• This research examines the long-term effects of semaglutide compared to other obesity treatments on kidney and mortality outcomes.
• Over a 2-year period, routine care data was analyzed.
• Comparisons were made between semaglutide, naltrexone-bupropion, and phentermine-topiramate.
• Atherogenic lipid levels and kidney laboratory results were measured.
• Semaglutide users showed lower atherogenic lipid levels than those using alternative treatments.
• Lower hazards of death and major adverse kidney events (MAKEs) were associated with semaglutide.
• Kidney laboratory differences between treatments were generally limited.